Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

28.19B

Market cap28.19B

Price-Earnings ratio

20.46

Price-Earnings ratio20.46

Dividend yield

—

Dividend yield—

Average volume

1.05M

Average volume1.05M

High today

$192.10

High today$192.10

Low today

$188.86

Low today$188.86

Open price

$190.47

Open price$190.47

Volume

351.30K

Volume351.30K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$115.25

52 Week low$115.25

Stock Snapshot

The current Biogen(BIIB) stock price is $190.95, with a market capitalization of 28.19B. The stock trades at a price-to-earnings (P/E) ratio of 20.46.

During the trading session on 2026-05-07, Biogen(BIIB) shares reached a daily high of $192.10 and a low of $188.86. At a current price of $190.95, the stock is +1.1% higher than the low and still -0.6% under the high.

Trading volume for Biogen(BIIB) stock has reached 351.3K, versus its average volume of 1.05M.

The stock's 52-week range extends from a low of $115.25 to a high of $202.41.

BIIB News

TipRanks 3d

Apellis Updates Executive Separation Plan Amid Biogen Merger

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 4d

How Investors Are Reacting To Biogen Earnings Beat, Lower Guidance, And Felzartamab China Deal

In April 2026, Biogen Inc. reported first-quarter 2026 results showing revenue of US$2.48 billion and net income of US$319.5 million, with earnings per share ri...

TipRanks 6d

Biogen upgraded to Buy from Hold at Freedom Broker

Freedom Broker analyst Ilya Zubkov upgraded Biogen (BIIB) to Buy from Hold with a price target of $245, up from $185. The firm views the company’s acquisition o...

Analyst ratings

53%

of 38 ratings

Buy

52.6%

Hold

42.1%

Sell

5.3%

More BIIB News

Simply Wall St 6d

Assessing Biogen Valuation After Strong 1 Year Gains And Mixed Longer Term Returns

Biogen (BIIB) is back in focus after recent trading left the stock around $189.28, with returns over the past month and past 3 months contrasting with a weaker...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.